Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AZD0305
- Development stage
- Phase 2
- Lead developer
- AstraZeneca
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
AZD0305 is a first-in-class antibody-drug conjugate (ADC) developed by AstraZeneca for the treatment of relapsed or refractory multiple myeloma. It specifically targets G protein-coupled receptor class 5 member D (GPRC5D), a protein highly expressed on myeloma cells. By binding to GPRC5D, AZD0305 delivers a cytotoxic payload directly to malignant plasma cells, leading to their destruction. In addition to its direct cytotoxic effects, it may also induce tumor cell killing through antibody-dependent cellular cytotoxicity. The drug is currently being evaluated in Phase I/II clinical trials as both monotherapy and in combination with other anticancer agents for patients who have exhausted standard treatment options.
- Other names
- anti-GPRC5D ADCanti-GPRC-5D ADCanti-GPRC 5D ADC
02
Targets
GPRC5D
Beyond the preview
Go deeper on AZD0305.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AZD0305.